AOTMiT: Transparency Council, incl. about drugs for MS and psoriasis

The agenda includes:
Preparation of a position on the assessment of the legitimacy of including the service "Cross-linking keratoconus surgery" (ICD-10 H18.6) into the list of guaranteed benefits in the field of hospital treatment.
Preparation of drug assessment positions:
• Ponvory (ponesimodum) as part of the drug program: B.29. "Treatment of multiple sclerosis (ICD-10 G 35)",
• Bimzelx (bimekizumabum) under the drug program: B.47. "Treatment of moderate to severe plaque psoriasis (ICD-10: L40.0)"
Preparation of positions on the legitimacy of granting consent for reimbursement of medicinal products:
• Vivitrol (naltrexone for extended-release injectable suspension) in the indication: mental and behavioral disorders due to alcohol use (F10), including addiction syndrome,
• Impavido (miltefosinum) in the indication: visceral leishmaniasis (ICD-10: B55.0) in the course of human immunodeficiency virus (HIV) infection.
Preparation of an opinion on the coverage of drugs containing active substances with reimbursement:
• mycophenolas mofetil in the indication: autoimmune diseases in immunodeficient patients; cytopenia in the course of autoimmune lymphoproliferative syndrome,
• sirolimusum in the indication: cytopenia in the course of autoimmune lymphoproliferative syndrome - resistant to the use of steroids or with excessively severe side effects of chronic steroid therapy in high doses.

Source: AOTMiT